Biocryst Pharmaceuticals Overview
Latest P/E ratio for Biocryst Pharmaceuticals: -6.83 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-6.83
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Biocryst Pharmaceuticals (BCRX) currently reports a P/E ratio of -6.83. That is below the Healthcare sector average of 25.9. Use the charts on this page to explore Biocryst Pharmaceuticals's P/E ratio history and peer comparisons.
Biocryst Pharmaceuticals's P/E ratio of -6.83 is lower than the Healthcare sector average of 25.9. That is roughly 126.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Biocryst Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -6.83, BCRX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -6.83, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.9. From there, open related valuation or income-statement pages for Biocryst Pharmaceuticals, and consider following BCRX for alerts when major investors trade the stock.
Biocryst Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -6.83 versus a sector average near 25.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCRX with unrelated industries.
